Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in chronic graft versus host disease
NCT02841995Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Started Sep 2016; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02841995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841995.